The table below shows Eterna Therapeutics Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$7.02M
-$15.84M
-$20.41M
-$20.98M
-$23.49M
-$8.10M
Capital expenditure
$37.00K
$369.00K
$19.00K
$297.00K
$154.00K
$39.00K
Investing cash flow
-$37.00K
-$365.00K
-$19.00K
-$47.00K
-$22.74M
-$39.00K
Dividends paid
-
-
-
-
ERNA operating cash flow (10-K history)
Eterna Therapeutics Inc. reported operating cash flow of -$7.02M for fiscal year 2025. That is up 55.7% from -$15.84M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from $23.00K (FY 2016) to -$7.02M. Figures come from the company's audited annual reports as filed with the SEC.